Significant advances are being made in screening and diagnosis which have the potential to radically reduce the costs, whilst improving the accessibility and reach of programmes. 

In combination with advancements in medical products (3D Breast Ultrasound, Digital Tomosynthesis), AI for computer-aided diagnosis and broader adoption of digital patient & citizen engagement - screening services, patient experience and cost per QALY could be positively impacted in coming years.